Fitzgerald Trae 4

What Happened
Trae Fitzgerald, Viemed Healthcare’s Chief Financial Officer, had restricted/phantom awards convert/vest on January 21, 2026, resulting in the acquisition of 16,646 underlying shares (13,317 + 3,329). To satisfy tax withholding and cash settlement, 4,246 shares were withheld for taxes and 3,329 shares were surrendered to the company, producing proceeds of $31,803 and $24,934 respectively (total ≈ $56,737). Per-share value used in the filing is $7.49 (market close on Jan 21, 2026).

Key Details

• Transaction date: January 21, 2026; Form 4 filed January 23, 2026 (filed within normal reporting window).
• Actions reported: conversion/exercise of derivatives/RSUs (transaction code M), tax withholding (F), and disposition to issuer (D).
• Shares acquired via conversion/vesting: 16,646 (13,317 + 3,329).
• Shares disposed (withheld/surrendered): 7,575 (4,246 withheld for taxes; 3,329 surrendered to issuer).
• Cash amount reported from dispositions: $31,803 (tax withholding) + $24,934 (surrender) = $56,737.
• Footnotes: RSUs represent one common share each (F1, F5); some awards were cash-settled phantom shares (F4, F6) — the filing reports the simultaneous acquisition of underlying shares and their disposition back to the company for cash.
• Shares owned after the transaction: not disclosed in the provided filing details.

Context
This filing reflects vesting/conversion of restricted stock units and phantom share units and routine withholding/surrender to cover tax obligations and cash settlement — not an open-market sale for investment purposes. For derivative entries showing $0.00, the filing treats the conversion/settlement of phantom units and the simultaneous cash disposition of the resulting underlying shares as reflected in the footnotes.